MicroPort® Announces Important Follow-up Results at ESC Congress 2022

Barcelona, Spain, 16 September 2022 – MicroPort Scientific Corporation (“MicroPort®”) recently participated in the European Society of Cardiology (ESC) Congress 2022 in Barcelona, together with its subsidiaries, Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort® Coronary”) and Hemovent GmbH (“Hemovent™”). MicroPort® released the 5-year long-term follow-up results of the clinical trial of Firehawk® Coronary Rapamycin-Targeted Eluting Stent System (“Firehawk®”) in a broad all-comers population, referred to as “TARGET AC”. Hemovent™ presented its products in front of the European physicians, attracting a large number of attendees.

Prof. Alexandra Lansky from Yale University School of Medicine, New Haven, US, presented the results of TARGET AC. The 5-year target lesion failure (TLF) was compared between the Firehawk® group and the industry-leading stent group, revealing a rate of 17.1% and 16.3% respectively, and no statistical difference (p=0.68). In addition, the reported stent thrombosis rate was 2.8% vs. 3.0% (p=0.81), with no statistical difference. The results demonstrate the incidence of very late stent thrombosis of the Firehawk® was low, with 1.3% in the Firehawk® group and 1.9% in the industry-leading stent group (p=0.20). Additionally, long-term safety and effectiveness of the Firehawk® as a coronary stent system with the lowest drug dosage was reported.

Prof. Niels van Royen from Radboud University Medical Center, Nijmegen, the Netherlands announced the results of subgroup analysis of patients with diabetes and acute coronary syndromes in TARGET AC. Compared with non-diabetic patients, those with diabetes had significantly lower safety and efficacy rates, including TLF, PoCE, TV-MI, ID-TLR, and stent thrombosis rates. Firehawk® stent is as safe and effective as the control stent in both patients with and without diabetes.

Prof. Giuseppe Tarantiti from the University of Padova, Italy, introduced the ongoing TARGET FIRST study, a unique clinical trial to test the usage of short dual antiplatelet therapy in the low-loading Firehawk® stent for complete revascularization in patients with acute myocardial infarction. In addition, Prof. Tarantiti introduced the FUTURE II trial of the second generation, fully bioresorbable vascular scafforlds system, Firesorb® Bioresorbable Rapamycin-Targeted Eluting Coronary Scaffold System (“Firesorb®”). The FUTURE II trial is designed to compare the safety and efficacy of Firesorb® and a market-leading stent. The results showed the rate of TLF and PoCE with Firesorb® was not significantly different from controls, and no device-related thrombotic events occurred in either group.

Moreover, Hemovent™ exhibited MOBYBOX®, the first fully integrated Extracorporeal Life Support (ECLS) system with Extracorporeal Membrane Oxygenation (ECMO). MicroPort® fully presented its diverse products at ESC Congress 2022, and it will further develop innovative products to provide complete solutions for patients worldwide.

About Shanghai MicroPort Medical (Group) Co., Ltd.

Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicoPort® will continue to steadily promote the target global clinical research program, enrich the cardiovascular interventional therapy product line with the support of accumulated clinical research data, and provide patients with more high-quality and inclusive integrated solutions.

About Hemovent™

Hemovent GmbH, based in Aachen, Germany (Hemovent™), a subsidiary and Innovation Lab of MicroPort Scientific Corporation (MicroPort®, stock code: 00853.HK), is a developer and manufacturer of highly innovative extracorporeal life support (ECLS) and extracorporeal membrane oxygenation (ECMO) products. Its flagship product, the MOBYBOX™ system, is the world’s first fully integrated and self-contained ECLS system for the treatment of cardiac and/or respiratory failure. It is extremely easy to use and surpasses all existing technologies in terms of size and transportability. Hemovent™ is committed to deliver best-in-class medical devices to save patients’ lives during severe cardiac or respiratory failure, which affect about 12 million people worldwide every year.